Summary

Commonly reported side effects of lanreotide include: diarrhea. Other side effects include: cholelithiasis, hypertension, and sinus bradycardia. Continue reading for a comprehensive list of adverse effects.

Applies to lanreotide: parenteral injection.

Side effects include:

Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, cholelithiasis, injection site reactions, arthralgia, headache, musculoskeletal pain, hyperglycemia, hypertension, dizziness, and muscle spasm.

For Healthcare Professionals

Applies to lanreotide: subcutaneous solution.

General

The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools

Common (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia

Uncommon (0.1% to 1%): Pancreatitis, feces discolored

Frequency not reported: Steatorrhea^[Ref]

In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.^[Ref]

Hepatic

Very common (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis

Common (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation

Uncommon (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal

Frequency not reported: Cholecystitis

Postmarketing reports: Steatorrhea, pancreatitis^[Ref]

Cardiovascular

Very common (10% or more): Bradycardia (18%), hypertension (14%)

Common (1% to 10%): Sinus bradycardia

Uncommon (0.1% to 1%): Other cardiac adverse drug reactions^[Ref]

Local

Very common (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)

Postmarketing reports: Persisting induration, injection site abscess^[Ref]

Metabolic

Very common (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)

Common (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased

Uncommon (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated^[Ref]

Hematologic

Very common (10% or more): Anemia (14%)^[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (19%), arthralgia (11%)^[Ref]

Nervous system

Very common (10% or more): Headache (16%)

Common (1% to 10%): Dizziness

Postmarketing reports: Dysautonomia^[Ref]

Respiratory

Common (1% to 10%): Dyspnea^[Ref]

Psychiatric

Common (1% to 10%): Depression

Uncommon (0.1% to 1%): Insomnia^[Ref]

Other

Common (1% to 10%): Fatigue

Uncommon (0.1% to 1%): Hot flush, asthenia

Postmarketing reports: Malaise^[Ref]

Immunologic

Common (1% to 10%): Anti-lanreotide antibodies^[Ref]

Hypersensitivity

Frequency not reported: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)^[Ref]

Dermatologic

Common (1% to 10%): Alopecia, hypotrichosis^[Ref]

Endocrine

Rare (less than 0.1%): Clinical hypothyroidism

Frequency not reported: Slight decreases in thyroid function^[Ref]